Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyldopa. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | BLM | P54132 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 3/20 | 1.00 |
| ▸ | APEX1 | P27695 | 3/20 | 1.00 |
| ▸ | RECQL | P46063 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyldopa (Racemic) SCHEMBL196981 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1172822 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL29352376 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL30176814 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL1321546 | 1.00 | KDM4E (1.00) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL5929436 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL259452 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL5370162 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa (Racemic) SCHEMBL29013197 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM | |
| Methyldopa SCHEMBL11452341 | 0.98 | KDM4E (0.97) | KDM4EHSD17B10TDP1MAPTBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 23775 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144903-A1 | RADIONUCLIDE-LABELED BORON-CONTAINING DRUG, AND PREPARATION AND USE THEREOF | Chengdu New Radiomedicine Technology Co., Ltd. (CN) | 2026-05-28 | — | — | US | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4736841-A1 | A MUCOADHESIVE LAYER FOR BUCCAL ADMINISTRATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT | IQ medical GmbH (DE) | 2026-05-06 | — | — | EP | claimed |
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4717276-A2 | OPHTHALMIC COMPOSITIONS COMPRISING LEVODOPA, AN ANTIOXIDANT AND AN AQUEOUS CARRIER | University of Canberra (AU) | 2026-04-01 | — | — | EP | claimed |
| EP-4704826-A1 | COMPOSITIONS AND METHODS FOR TREATING POST-TRAUMATIC STRESS DISORDER | Yale University (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | claimed |
| US-12564596-B2 | Agents and methods for modulating pathogen activity | GRIFFITH UNIVERSITY (AU) | 2026-03-03 | — | — | US | claimed |
| US-12533417-B2 | L-DOPA and/or DOPA decarboxylse inhibitors conjugated to sugar for the treatment of dopamine-responsive disorders | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2026-01-27 | — | — | US | claimed |
| EP-4674433-A2 | PULSATILE DRUG DELIVERY SYSTEM FOR TREATING MORNING AKINESIA | Contera Pharma A/S (DK) | 2026-01-07 | — | — | EP | claimed |
| US-4221813-A | L-A-METHYL-3,4-DIHYDROXY-PHENYLALANINE | MERCK & CO., INC. (US) | 1980-09-09 | — | — | US | claimed |
| EP-0012401-A1 | Carboxyalkyl dipeptide derivatives, process for preparing them and pharmaceutical composition containing them | MERCK & CO. INC. (US) | 1980-06-25 | — | — | EP | claimed |
| EP-0011868-A1 | Methyldopa composition | MERCK & CO. INC. (US) | 1980-06-11 | — | — | EP | claimed |
| US-4182764-A | DIURETIC, URICOSURIC | MERCK & CO., INC. (US) | 1980-01-08 | — | — | US | claimed |
| US-4177285-A | DIURETICS, HYPOTENSIVES | MERCK & CO., INC. (US) | 1979-12-04 | — | — | US | claimed |
| EP-0005074-A1 | A material and composition for reducing blood pressure | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1979-10-31 | — | — | EP | claimed |
| US-4096267-A | (1-Oxo-2-aryl or thienyl-2-substituted-5-indanyloxy (or thio) alkanoic acids, and derivatives thereof | MERCK & CO., INC. (US) | 1978-06-20 | — | — | US | claimed |
| US-4087520-A | Lowering blood pressure with new L-3-(3,4-dihydroxyphenyl)-2-methyl-alanine peptides | BOEHRINGER MANNHEIM GMBH (DT) | 1978-05-02 | — | — | US | claimed |
| US-4016288-A | ANIMALS, A-HYDRAZINO-3,4-DIHYDROXY-PHENYL-PROPIONIC ACID WITH AN ALANINATE | MERCK & CO., INC. (US) | 1977-04-05 | — | — | US | claimed |
| US-3988341-A | Esterification process | MERCK & CO., INC. (US) | 1976-10-26 | — | — | US | claimed |